JP2017518372A5 - - Google Patents

Download PDF

Info

Publication number
JP2017518372A5
JP2017518372A5 JP2017515026A JP2017515026A JP2017518372A5 JP 2017518372 A5 JP2017518372 A5 JP 2017518372A5 JP 2017515026 A JP2017515026 A JP 2017515026A JP 2017515026 A JP2017515026 A JP 2017515026A JP 2017518372 A5 JP2017518372 A5 JP 2017518372A5
Authority
JP
Japan
Prior art keywords
seq
composition
complementary sequence
guide rna
ebv genome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017515026A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017518372A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/033186 external-priority patent/WO2015184262A1/en
Publication of JP2017518372A publication Critical patent/JP2017518372A/ja
Publication of JP2017518372A5 publication Critical patent/JP2017518372A5/ja
Pending legal-status Critical Current

Links

JP2017515026A 2014-05-30 2015-05-29 潜伏性ウイルス感染用の処置剤を送達するための組成物および方法 Pending JP2017518372A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462005395P 2014-05-30 2014-05-30
US62/005,395 2014-05-30
US201462029072P 2014-07-25 2014-07-25
US62/029,072 2014-07-25
PCT/US2015/033186 WO2015184262A1 (en) 2014-05-30 2015-05-29 Compositions and methods of delivering treatments for latent viral infections

Publications (2)

Publication Number Publication Date
JP2017518372A JP2017518372A (ja) 2017-07-06
JP2017518372A5 true JP2017518372A5 (https=) 2018-07-05

Family

ID=53366336

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017515025A Pending JP2017518075A (ja) 2014-05-30 2015-05-29 潜伏性ウイルス感染を処置するための組成物および方法
JP2017515026A Pending JP2017518372A (ja) 2014-05-30 2015-05-29 潜伏性ウイルス感染用の処置剤を送達するための組成物および方法
JP2019205922A Pending JP2020043862A (ja) 2014-05-30 2019-11-14 潜伏性ウイルス感染を処置するための組成物および方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017515025A Pending JP2017518075A (ja) 2014-05-30 2015-05-29 潜伏性ウイルス感染を処置するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019205922A Pending JP2020043862A (ja) 2014-05-30 2019-11-14 潜伏性ウイルス感染を処置するための組成物および方法

Country Status (10)

Country Link
US (7) US10066241B2 (https=)
EP (3) EP3149171A1 (https=)
JP (3) JP2017518075A (https=)
KR (1) KR20170005494A (https=)
CN (2) CN106574256A (https=)
AU (3) AU2015266776A1 (https=)
BR (1) BR112016028023A2 (https=)
CA (2) CA2949710A1 (https=)
SG (1) SG11201610028TA (https=)
WO (3) WO2015184262A1 (https=)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6261500B2 (ja) 2011-07-22 2018-01-17 プレジデント アンド フェローズ オブ ハーバード カレッジ ヌクレアーゼ切断特異性の評価および改善
EP3919505B1 (en) 2013-01-16 2023-08-30 Emory University Uses of cas9-nucleic acid complexes
SI2986729T1 (sl) 2013-04-16 2019-02-28 Regeneron Pharmaceuticals, Inc. Ciljana sprememba genoma podgane
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9925248B2 (en) 2013-08-29 2018-03-27 Temple University Of The Commonwealth System Of Higher Education Methods and compositions for RNA-guided treatment of HIV infection
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9546384B2 (en) 2013-12-11 2017-01-17 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a mouse genome
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
EP3149171A1 (en) 2014-05-30 2017-04-05 The Board of Trustees of The Leland Stanford Junior University Compositions and methods of delivering treatments for latent viral infections
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
ES2731437T3 (es) 2014-11-21 2019-11-15 Regeneron Pharma Métodos y composiciones para la modificación genética dirigida mediante el uso de pares de ARN guías
US10900034B2 (en) 2014-12-03 2021-01-26 Agilent Technologies, Inc. Guide RNA with chemical modifications
US10059940B2 (en) * 2015-01-27 2018-08-28 Minghong Zhong Chemically ligated RNAs for CRISPR/Cas9-lgRNA complexes as antiviral therapeutic agents
EP3280803B1 (en) 2015-04-06 2021-05-26 The Board of Trustees of the Leland Stanford Junior University Chemically modified guide rnas for crispr/cas-mediated gene regulation
US20160346360A1 (en) * 2015-05-29 2016-12-01 Agenovir Corporation Compositions and methods for cell targeted hpv treatment
EP3331582A4 (en) * 2015-05-29 2019-08-07 Agenovir Corporation METHODS AND COMPOSITIONS FOR THE TREATMENT OF TRANSPLANTATION CELLS
US20160346362A1 (en) * 2015-05-29 2016-12-01 Agenovir Corporation Methods and compositions for treating cytomegalovirus infections
US10117911B2 (en) 2015-05-29 2018-11-06 Agenovir Corporation Compositions and methods to treat herpes simplex virus infections
HK1258900A1 (zh) * 2015-09-29 2019-11-22 埃吉诺维亚公司 递送方法和组合物
WO2017068077A1 (en) 2015-10-20 2017-04-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and products for genetic engineering
JP7109784B2 (ja) 2015-10-23 2022-08-01 プレジデント アンド フェローズ オブ ハーバード カレッジ 遺伝子編集のための進化したＣａｓ９蛋白質
EP3387001A4 (en) 2015-12-09 2019-08-14 Excision Biotherapeutics, Inc. GENETIZATION METHOD AND AGENT TO ELIMINATE THE RISK OF JC VIRUS ACTIVATION AND PML (PROGRESSIVE MULTIFOCALER LEUKOENCEEPHALOPATHY) DURING IMMUNOSUPPRESSIVE THERAPY
CA3011270A1 (en) * 2016-01-25 2018-06-14 Temple University Of The Commonwealth System Of Higher Education Rna guided eradication of human jc virus and other polyomaviruses
AU2017211062A1 (en) * 2016-01-25 2018-06-07 Excision Biotherapeutics Methods and compositions for RNA-guided treatment of HIV infection
CA3015353A1 (en) * 2016-02-25 2017-08-31 Agenovir Corporation Viral and oncoviral nuclease treatment
US20170246260A1 (en) * 2016-02-25 2017-08-31 Agenovir Corporation Modified antiviral nuclease
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
WO2017192172A1 (en) * 2016-05-05 2017-11-09 Temple University - Of The Commonwealth System Of Higher Education Rna guided eradication of varicella zoster virus
JP2019519250A (ja) * 2016-05-10 2019-07-11 ユナイテッド ステイツ ガバメント アズ リプレゼンテッド バイ ザ デパートメント オブ ベテランズ アフェアーズＵｎｉｔｅｄ Ｓｔａｔｅｓ Ｇｏｖｅｒｎｍｅｎｔ Ａｓ Ｒｅｐｒｅｓｅｎｔｅｄ Ｂｙ Ｔｈｅ Ｄｅｐａｒｔｍｅｎｔ Ｏｆ Ｖｅｔｅｒａｎｓ Ａｆｆａｉｒｓ Ｈｉｖ−１感染と複製に必須な遺伝子を切断するｃｒｉｓｐｒ／ｃａｓの構築物のレンチウィルスによる送達
IL323024A (en) 2016-05-20 2025-10-01 Regeneron Pharma Methods for breaking immunological tolerance using multiple guide RNAs
WO2017210380A1 (en) * 2016-06-01 2017-12-07 Excision Biotherapeutics, Inc. Compositions and methods of treatment for lytic and lysogenic viruses
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
AU2017285224B2 (en) * 2016-06-14 2023-05-18 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
KR102547316B1 (ko) 2016-08-03 2023-06-23 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
WO2018045284A1 (en) * 2016-09-02 2018-03-08 The General Hospital Corporation Methods and systems for non-contact construction of an internal structure
IL265921B2 (en) 2016-10-14 2024-05-01 Prec Biosciences Inc Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
EP3526320A1 (en) 2016-10-14 2019-08-21 President and Fellows of Harvard College Aav delivery of nucleobase editors
WO2018112225A1 (en) * 2016-12-14 2018-06-21 The J. David Gladstone Institutes Methods and compositions for generating a deletion library and for identifying a defective interfering particle (dip)
CN106729753A (zh) * 2016-12-16 2017-05-31 谭旭 抗乙型肝炎病毒的递送系统和生物制剂
WO2018118587A1 (en) * 2016-12-22 2018-06-28 Agenovir Corporation Modified polynucleotides for antiviral therapy
WO2018118586A1 (en) * 2016-12-22 2018-06-28 Agenovir Corporation Antiviral/endogenous combination therapy
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
US20190071673A1 (en) * 2017-01-18 2019-03-07 Thomas Malcolm CRISPRs WITH IMPROVED SPECIFICITY
US20180201921A1 (en) * 2017-01-18 2018-07-19 Excision Biotherapeutics, Inc. CRISPRs
WO2018140269A1 (en) * 2017-01-26 2018-08-02 Excision Biotherapeutics, Inc. Lentivirus and non-integrating lentivirus as viral vector to deliver crispr therapeutic
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
JP2020510038A (ja) 2017-03-09 2020-04-02 プレジデント アンド フェローズ オブ ハーバード カレッジ がんワクチン
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
CA3057192A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
EP3635121A1 (en) * 2017-06-02 2020-04-15 Institut National de la Sante et de la Recherche Medicale (INSERM) Viral vector combining gene therapy and genome editing approaches for gene therapy of genetic disorders
WO2019023680A1 (en) 2017-07-28 2019-01-31 President And Fellows Of Harvard College METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE)
MX2020002148A (es) * 2017-08-25 2020-07-20 Ovid Therapeutics Inc Vectores adenoasociados recombinantes.
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
KR20250107288A (ko) 2017-10-16 2025-07-11 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
WO2019118949A1 (en) 2017-12-15 2019-06-20 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
WO2019204210A1 (en) * 2018-04-16 2019-10-24 Georgia Tech Research Corporation Mrna driven expression of rna editors for treatment of pathologies
EP3797160A1 (en) 2018-05-23 2021-03-31 The Broad Institute Inc. Base editors and uses thereof
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
CN109943563A (zh) * 2019-03-08 2019-06-28 内蒙古大学 CRISPR-Cas9系统介导的狂犬病病毒基因组敲除的方法
JP7657726B2 (ja) 2019-03-19 2025-04-07 ザ ブロード インスティテュート，インコーポレーテッド 編集ヌクレオチド配列を編集するための方法および組成物
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
WO2020245783A2 (en) * 2019-06-06 2020-12-10 Tata Consultancy Services Limited Method and system for identification of target sites in protein coding regions for combating pathogens
CN112168808B (zh) * 2019-07-02 2023-01-24 深圳市第二人民医院 一种基于crispr的细胞核靶向药物递送系统
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
US12410418B2 (en) 2019-12-06 2025-09-09 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
DE112021002672T5 (de) 2020-05-08 2023-04-13 President And Fellows Of Harvard College Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz
CN112795696A (zh) * 2020-12-31 2021-05-14 北京思尔成生物技术有限公司 乙型肝炎病毒pgRNA芯片数字PCR绝对定量检测试剂盒及方法
WO2022261150A2 (en) 2021-06-09 2022-12-15 Scribe Therapeutics Inc. Particle delivery systems
JP2024534945A (ja) 2021-09-10 2024-09-26 アジレント・テクノロジーズ・インク 化学修飾を有するプライム編集のためのガイドｒｎａ
CN114196556B (zh) * 2021-12-31 2023-08-01 重庆大学 一种高毒力蝗绿僵菌菌株及其构建方法
WO2023221937A1 (zh) * 2022-05-16 2023-11-23 上海行深生物科技有限公司 递送自复制rna分子的方法
IL324634A (en) 2023-05-15 2026-01-01 Nchroma Bio Inc Compositions and methods for epigenetic regulation of hbv gene expression

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1003131A (en) * 1910-08-17 1911-09-12 Leonard F Bellingrath Valve operating and indicating mechanism.
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5580571A (en) 1991-10-15 1996-12-03 Hostetler; Karl Y. Nucleoside analogues
SE9200951D0 (sv) 1992-03-27 1992-03-27 Kabi Pharmacia Ab Pharmaceutical composition containing a defined lipid system
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5356802A (en) 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
EP0642589A4 (en) * 1992-05-11 1997-05-21 Ribozyme Pharm Inc METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION.
EP0702516A4 (en) 1993-06-01 1998-04-22 Life Technologies Inc GENETIC IMMUNIZATION WITH CATIONIC LIPIDS
US6242568B1 (en) 1994-01-18 2001-06-05 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
ATE524545T1 (de) 1994-08-20 2011-09-15 Gendaq Ltd Verbesserungen bei oder im zusammenhang mit bindeproteinen zur erkennung von dna
US5789538A (en) 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
US6410248B1 (en) 1998-01-30 2002-06-25 Massachusetts Institute Of Technology General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
US6383481B1 (en) 1998-03-30 2002-05-07 Japan Immunoresearch Laboratories Co., Ltd. Method for transplantation of hemopoietic stem cells
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
EP1233781A1 (en) * 1999-11-24 2002-08-28 Oklahoma Medical Research Foundation Assays and therapies for latent viral infection
WO2004027036A2 (en) * 2002-09-19 2004-04-01 Johns Hopkins University School Of Medicine Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US7888121B2 (en) * 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
CN101144817B (zh) * 2003-08-20 2011-10-05 香港神农有限公司 一种eb病毒蛋白酶联免疫吸附诊断试剂盒及其制备方法
WO2005028634A2 (en) * 2003-09-18 2005-03-31 Emory University Improved mva vaccines
EP2410044B1 (en) 2004-12-29 2022-06-22 Hadasit Medical Research Services And Development Ltd. Stem cells culture systems
CA2891996A1 (en) * 2005-10-18 2007-04-26 Duke University Rationally-designed meganucleases with altered sequence specificity and dna-binding affinity
JP5492418B2 (ja) 2005-11-18 2014-05-14 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション ウイルス関連疾患を予防するためのウイルス遺伝子産物およびワクチン接種の方法
GB0526211D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Viral vectors
JP5266210B2 (ja) 2006-05-25 2013-08-21 サンガモ バイオサイエンシズ インコーポレイテッド 改変開裂ハーフドメイン
WO2009024834A2 (en) * 2006-12-05 2009-02-26 Rosetta Genomics Ltd Nucleic acids involved in viral infection
US20100076057A1 (en) 2008-09-23 2010-03-25 Northwestern University TARGET DNA INTERFERENCE WITH crRNA
US20110023144A1 (en) 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in amyotrophyic lateral sclerosis disease
CN101880649B (zh) 2009-05-05 2012-09-05 中国福利会国际和平妇幼保健院 一种干细胞培养方法
WO2011119628A2 (en) * 2010-03-23 2011-09-29 The Regents Of The University Of California Compositions and methods for self-adjuvanting vaccines against microbes and tumors
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
WO2013141680A1 (en) 2012-03-20 2013-09-26 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
CN103361328B (zh) * 2012-03-30 2017-08-18 复旦大学 介导整合的hiv‑1前病毒基因敲除的锌指核酸内切酶及其制法和应用
EP3241902B1 (en) 2012-05-25 2018-02-28 The Regents of The University of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
US9102936B2 (en) 2012-06-11 2015-08-11 Agilent Technologies, Inc. Method of adaptor-dimer subtraction using a CRISPR CAS6 protein
US20150315576A1 (en) 2012-11-01 2015-11-05 Massachusetts Institute Of Technology Genetic device for the controlled destruction of dna
WO2014093479A1 (en) 2012-12-11 2014-06-19 Montana State University Crispr (clustered regularly interspaced short palindromic repeats) rna-guided control of gene regulation
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
CN105121648B (zh) 2012-12-12 2021-05-07 布罗德研究所有限公司 用于序列操纵的系统、方法和优化的指导组合物的工程化
WO2014093718A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
CA2894684A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Engineering and optimization of improved crispr-cas systems, methods and enzyme compositions for sequence manipulation in eukaryotes
DK2931897T3 (en) * 2012-12-12 2018-02-05 Broad Inst Inc CONSTRUCTION, MODIFICATION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTICAL APPLICATIONS
DK2931898T3 (en) 2012-12-12 2016-06-20 Massachusetts Inst Technology CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS
CA2895155C (en) 2012-12-17 2021-07-06 President And Fellows Of Harvard College Rna-guided human genome engineering
EP3919505B1 (en) 2013-01-16 2023-08-30 Emory University Uses of cas9-nucleic acid complexes
US10660943B2 (en) 2013-02-07 2020-05-26 The Rockefeller University Sequence specific antimicrobials
WO2014143381A1 (en) 2013-03-09 2014-09-18 Agilent Technologies, Inc. Methods of in vivo engineering of large sequences using multiple crispr/cas selections of recombineering events
MX374090B (es) 2013-03-14 2025-03-05 Caribou Biosciences Inc Composiciones y métodos de ácidos nucleicos dirigidos al ácido nucleico.
US20140349400A1 (en) 2013-03-15 2014-11-27 Massachusetts Institute Of Technology Programmable Modification of DNA
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
US20140273230A1 (en) 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
AU2014227653B2 (en) 2013-03-15 2017-04-20 The General Hospital Corporation Using RNA-guided foki nucleases (RFNs) to increase specificity for RNA-guided genome editing
JP6576904B2 (ja) 2013-04-04 2019-09-18 トラスティーズ・オブ・ダートマス・カレッジ ＨＩＶ−１プロウイルスＤＮＡのｉｎｖｉｖｏ切除のための組成物及び方法
US20160186208A1 (en) 2013-04-16 2016-06-30 Whitehead Institute For Biomedical Research Methods of Mutating, Modifying or Modulating Nucleic Acid in a Cell or Nonhuman Mammal
CN105683376A (zh) 2013-05-15 2016-06-15 桑格摩生物科学股份有限公司 用于治疗遗传病状的方法和组合物
US11414695B2 (en) 2013-05-29 2022-08-16 Agilent Technologies, Inc. Nucleic acid enrichment using Cas9
JP7120717B2 (ja) 2013-07-09 2022-08-17 プレジデント アンド フェローズ オブ ハーバード カレッジ 多重ｒｎａ誘導型ゲノム編集
US9663782B2 (en) 2013-07-19 2017-05-30 Larix Bioscience Llc Methods and compositions for producing double allele knock outs
US9925248B2 (en) 2013-08-29 2018-03-27 Temple University Of The Commonwealth System Of Higher Education Methods and compositions for RNA-guided treatment of HIV infection
WO2015034872A2 (en) 2013-09-05 2015-03-12 Massachusetts Institute Of Technology Tuning microbial populations with programmable nucleases
AU2014346559B2 (en) 2013-11-07 2020-07-09 Editas Medicine,Inc. CRISPR-related methods and compositions with governing gRNAs
BR112016013207A2 (pt) * 2013-12-12 2017-09-26 Massachusetts Inst Technology administração, uso e aplicações terapêuticas dos sistemas crispr-cas e composições para o hbv e distúrbios e doenças virais
EP3470089A1 (en) 2013-12-12 2019-04-17 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
MX2016007797A (es) 2013-12-19 2016-09-07 Amyris Inc Metodos para integracion genomica.
JP2017506893A (ja) 2014-02-18 2017-03-16 デューク ユニバーシティ ウイルス複製不活化組成物並びにその製造方法及び使用
WO2015153889A2 (en) 2014-04-02 2015-10-08 University Of Florida Research Foundation, Incorporated Materials and methods for the treatment of latent viral infection
CN103911376B (zh) 2014-04-03 2017-02-15 黄行许 CRISPR‑Cas9靶向敲除乙肝病毒cccDNA及其特异性sgRNA
EP3149171A1 (en) 2014-05-30 2017-04-05 The Board of Trustees of The Leland Stanford Junior University Compositions and methods of delivering treatments for latent viral infections

Similar Documents

Publication Publication Date Title
JP2017518372A5 (https=)
JP2017518075A5 (https=)
US11273209B2 (en) Methods and compositions for RNA-guided treatment of HIV infection
JP7522088B2 (ja) 単純ヘルペス１型および他の関連するヘルペスウイルスのｒｎａガイド除去
AU2017219605B2 (en) Excision of retroviral nucleic acid sequences
US9981020B2 (en) Methods and compositions for RNA-guided treatment of HIV infection
US20170247703A1 (en) Antiviral nuclease methods
JP2012509340A5 (https=)
WO2017132112A1 (en) Methods and compositions for rna-guided treatment of hiv infection
KR20170005494A (ko) 잠복 바이러스 감염에 대한 치료제를 전달하는 조성물 및 방법
WO2009012143A3 (en) Virus derived antimicrobial peptides
EP4600366A3 (en) Cas 9 retroviral integrase systems for targeted incorporation of a dna sequence into a genome of a cell
FI3981437T3 (fi) Nukleiinihapporokotteita
Azevedo-Pereira et al. Inhibition of HIV replication by host cellular factors
De Clercq Status presens of antiviral drugs and strategies: Part I: DNA viruses and retroviruses
De Clercq Status presens of antiviral drugs and strategies: Part II: RNA VIRUSES (EXCEPT RETROVIRUSES)
Sheikholeslami et al. Variant Cells and Viral Infections: Understanding Cellular Coping Mechanisms
Falqui Development of poxvirus-derived vectors to analyze novel ISG15 functions
WO2022256516A9 (en) Gene editing therapy for hiv infection via dual targeting of hiv genome and ccr5
WO2005100383A8 (en) Novel hiv+ infected cells targeting retroviral vectors and uses thereof for treatment of hiv infection
HK40000290A (en) Excision of retroviral nucleic acid sequences
Hastie Understanding and overcoming limitations of vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma
JP2010248179A (ja) 医薬組成物